Micromet/MedImmune’s Blinatumomab Shows Early Promise Of BiTE Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Immune-based cancer therapy demonstrated tumor regression and complete remission in non-Hodgkin’s lymphoma patients in an early study.
You may also be interested in...
MedImmune Returns BiTE Compound To Micromet With An Option To Jump Back In
Partners will start an all-new BiTE project and continue working on another, while Micromet takes over worldwide development of blinatumomab, for which MedImmune retains a commercialization option.
MedImmune Returns BiTE Compound To Micromet With An Option To Jump Back In
Partners will start an all-new BiTE project and continue working on another, while Micromet takes over worldwide development of blinatumomab, for which MedImmune retains a commercialization option.
Sign Of The Times? Micromet’s Stock Price Sluggish Despite Reasons For Optimism
Biotech well-funded thanks to recent deals and sees blockbuster potential in lymphoma with blinatumomab.